GlassScriptPhysician profile
Karen Kadas
NPI 1578903449
$796.99
in general payments reported to CMS, 2019-2025
11 companies · $198 in 2025
The $198 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $104 · 2022: $61.53 · 2023: $229 · 2024: $205 · 2025: $198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $631.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $631.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $188.61 | 2022-2025 | |
| Glaxosmithkline, LLC. | $166.51 | 2023-2024 | Shingrix, Arexvy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $122.00 | 2023-2025 | Caplyta |
| Indivior INC. | $114.72 | 2024-2025 | Sublocade |
| Janssen Pharmaceuticals, INC | $64.04 | 2021-2023 | Spravato |
| Novo Nordisk INC | $40.19 | 2021-2022 | |
| Abbott Laboratories | $25.81 | 2021 | |
| Pfizer INC. | $25.22 | 2021-2022 | |
| Grifols USA, LLC | $22.46 | 2024 | Prolastin-C Liquid |
| Teva Pharmaceuticals USA, INC. | $15.64 | 2025 | Austedo Xr |
| Astrazeneca Pharmaceuticals LP | $11.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Kadas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.